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Tumour angiogenesis, described by Folkman in the early seventies, is an essential, complex, and dynamic process necessary for the
growth of all solid tumours. Among the angiogenic factors secreted by the tumour cells, the Vascular Endothelial Growth Factor
(VEGF) is one of the most important. Most types of human cancer cells express elevated levels of this proangiogenic factor and
its receptors. New molecules, called anti-angiogenic, are developed to impair VEGF pathway and tumour vasculature. Despite
important results, the clinical beneﬁts of anti-VEGF therapy are relatively modest and usually measured in weeks or months.
Why following anti-angiogenic therapy do some patients respond transiently and then why does tumour grow again and disease
progress and which compensatory mechanisms could explain the anti-angiogenic treatment failure?
1.Introduction
Tumour angiogenesis, as described by Folkman in the early
seventies and conﬁrmed today [1], is an essential, complex,
and dynamic process necessary for the growth of all solid
tumours. It stipulates that a tumour cannot grow through
a deﬁned volume if it is not vascularized. The cores of
solid tumours rapidly undergo hypoxic with low oxygen
levels and nutrients deﬁciency. Tumour cells counteract
this process by producing angiogenic factors responsible
for growth and migration of quiescent endothelial cells of
proximal blood vessels. The consequence is the creation of
a new vascular network to supply the tumour with oxygen,
nutrients, growth factors, proteolytic enzymes, tumours
cells, and dissemination in host [2, 3]. Tumour angiogenesis
and hypoxia are considered as hallmarks of solid tumours
[4, 5]. Among the angiogenic factors secreted by tumour
cells, the Vascular Endothelial Growth Factor (VEGF) is one
of the most important. Diﬀerent stimuli are responsible of
its production. Among them hypoxia was one of the ﬁrst
described. During the angiogenic switch, the frail existing
balance between pro- and anti-angiogenic factors is broken
in favour of proangiogenic factors [6]. Most types of human
cancercellsexpresselevatedlevelsofVEGF.Theyalsoexpress
VEGF receptors at their surface including VEGF-R1,2,3,
VEGF-R3 participating to lymphangiogenesis [7–11]. All
these results have allowed the development of therapeutic
tools targeting VEGF (Bevacizumab) [12] or their receptors
(Tyrosine kinase inhibitors) [13].
2. Examples of AntiangiogenicTreatments
Commonly Used inMetastaticCancers
For example, Bevacizumab (Avastin, Roche), a humanized
neutralizing monoclonal antibody against VEGF, is the ﬁrst
anti-angiogenic molecule approved by the FDA in 2004. This
antibody, which is becoming an important anti-angiogenic
treatment, is commonly used in association with a cytotoxic
chemotherapy for late stages of colon cancer, nonsmall-
cell lung cancer, breast cancer, glioblastoma, and metastatic
renal cell carcinoma (mRCC). Sorafenib tosylate (Nexavar,
Bayer) and Sunitinib malate (Sutent, Pﬁzer), two small
tyrosine kinase inhibitors (TKI), target multiple signaling
pathways including VEGF and platelet-derived growth fac-
tors (PDGFs). Sorafenib and Sunitinib are approved by the
FDA to treat mRCC as a single agent. Sunitinib is used in2 Journal of Oncology
gastrointestinal stromal tumours (GISTs) and Sorafenib is
used for treating patients with liver cancer. Every year a
variety of new anti-angiogenic molecules are developed with
more than 800 clinical trials [14].
Despite important results, the clinical beneﬁts of anti-
VEGF therapy are relatively modest and usually measured in
weeks or months [15]. In some cases patients do not respond
to anti-VEGF treatments. For example, Bevacizumab used
as a single agent to treat colorectal and nonsmall-cell lung
t u m o u r si si n e ﬃcient [12, 16]. Recently a phase III study of
Bevacizumab plus chemotherapy in early-stage colon cancer
did not meet its primary endpoint for lowering the risk
of the cancer recurrence compared to chemotherapy alone
[17]. Discontinuous TKI treatments (4 weeks on/2 weeks
oﬀ) in patients with metastatic breast cancer or mRCC
can carry the risk of tumour progression during drug-free
break periods [18, 19]. Thereby, in a preclinical model, rapid
tumour revascularisation has been reported after removal
of anti-VEGF therapy [20]. Multiple angiogenesis inhibitors
have been therapeutically validated in preclinical cancer
models and several in clinical trials. Why following anti-
angiogenic therapy do somepatients respond transiently and
then why does tumour growth again and disease progress?
Which compensatory mechanisms could explain the anti-
angiogenic treatment resistance?
The fraction of nonresponsive patients included in
anti-angiogenic clinical trials such as anti-VEGF antibody
treatment or tyrosine kinase inhibitors is signiﬁcant [13,
15, 21]. In these cases anti-angiogenic treatment does not
permet to obtain beneﬁcial eﬀects. Hence, there is no
cessation or retardation of the tumour growth or increase
of survival. Resistance to anti-angiogenic agents can be
the result of intrinsic tumour resistances or acquired resis-
tances. Diﬀerent mechanisms can explain these resistances
including redundant angiogenic factors with upregulation
of alternative angiogenic signals, induction of hypoxia,
selection of more aggressive tumour cells, recruitment of
bone marrow-derived proangiogenic cells and inﬂammatory
cells invasion, modiﬁcation of vascular pericyte coverage,
and vessel cooption.
2.1. The Angiogenic Redundancy and Alternative Proangio-
genic Pathways. The angiogenic redundancy is the ﬁrst
resistance mechanism identiﬁed following anti-VEGF ther-
apy [22, 23]. VEGF is the predominant angiogenic fac-
tor in human tumours. However, during tumour devel-
opment redundant proangiogenic factors could be pro-
duced including Fibroblast Growth Factors (FGFs), Platelet
Derived Growth Factors (PDGFs), Placenta Growth Factor
(PlGF), and Tumour Necrosis Factor-α (TNF-α)[ 24–26]
(Figure 1(1)). For example, in early-stage breast cancers
VEGFisthemajorproangiogenicfactorwhereasinlate-stage
additional angiogenic molecules are produced including
FGF-2 [23].
Preclinical and clinical anti-VEGF studies have shown
that tumours can grow despite VEGF pathway inhibition
due to angiogenic redundancy. In a preclinical model of
pancreatic neuron-endocrine cancer, after few days of anti-
VEGFR2 antibody (DC101) treatment, the vascular density
of tumours is reduced and tumours have regions of acute
hypoxia. Histological analysis shows that tumours have a
wide front of tumour invasion compared to controls and
tumours are more invasive after one week of treatment
and this increases after four weeks of continuous treatment.
Despite the disruption of VEGF angiogenic switch follow-
ing long-term treatment, a phenotypic resistance to anti-
VEGFR2 therapy emerges. During this phase, the tumour’s
revascularization is increased indicating an active tumour
angiogenesis. This progression phase is linked to enhanced
production of redundant angiogenic factors, such as FGF
family members. If mice are treated with anti-VEGFR, then
with FGF-trap just before tumour vasculature regrowth, the
tumour growth and neovascularization are attenuated. This
independence of VEGF pathway is associated with hypoxia-
mediated induction of proangiogenic factors such as FGF-
1 and 2, ephrin A1 and 2, and angiopoietin 1 [22]. A
synergism between the low expression of two angiogenic
factors such as FGF-2 and PDGF-bb could be suﬃcient to
promote angiogenic response although it is expressed at
low levels [27, 28]. Following anti-VEGF therapy, levels of
plasmatic placental growth factor (PlGF) are increased and
seem to be implicated in the angiogenic redundancy [26,
29]. In experimental studies, VEGF-sensitive and resistant
tumours respond to PlGF antibody treatment, this antibody
enhances the eﬃciency of anti-VEGFR2 therapy, and it
reduces tumour angiogenesis and metastasis without induc-
ing hypoxia [24]. Moreover, anti-PlGF prevents inﬁltration
of angiogenic macrophages. However, clinical studies on
VEGF-trap, that binds both VEGF-A and PlGF, do not show
an additional beneﬁt compared to Bevacizumab. The with-
drawalofoneproangiogenicfactorcouldbecounterbalanced
by production of compensatory angiogenic growth factors
and/or chemokines leading to angiogenic rescue program
[30]. To prevent angiogenic redundancy diﬀerent actors
implicated in tumour angiogenesis might be targeted at the
same time.
2.2. Hypoxia: A Major Inducer of Angiogenic Redundancy.
Antiangiogenic therapies reduce and normalize tumour
vasculature but increase intratumour hypoxia [31, 32]
(Figure 1(2)). Hypoxia and overexpression of hypoxia-
inducedfactor-1(HIF-1)havebeenassociatedwithradiation
therapy and chemotherapy resistance, selection of invasive
and metastatic cells, and a poor clinical prognosis of solid
tumours [33]. HIF-1 is considered as the major regulator
of angiogenic actors following hypoxia. It regulates a lot
of genes involved in angiogenesis (VEGF, PlGF, VEGFR-
1), proliferation and migration of endothelial cells (such
as VEGF, PlGF, FGF2, CXCL12/CXCR4, PDGF), pericytes
recruitment (PDGF, Ang-1), and modiﬁcation of vascular
permeability (VEGF/VEGFR-1, Ang-2) [34, 35].
The treatment of recurrent glioblastoma patients with a
tyrosine kinase inhibitor targeting VEGF receptors initially
leads to disease stable but resistances appear after few weeks.
The development of resistance following VEGF blockade
is associated with an increase of circulating levels of basic
FGF, stromal cell-derived factor 1 alpha (SDF1α), two genesJournal of Oncology 3
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Figure 1: Molecular mechanisms involved in tumor anti-angiogenesis therapies resistance. (1) Following anti-VEGF therapies, redundant
angiogenic factors are produced by tumour cells. Antiangiogenic treatments reduce and normalize tumour vasculature but increase
intratumour hypoxia (2). Hypoxia induces SDF-1α which recruits BMDCs such as CD11b+Gr1+, redundant angiogenic factors (1), and
activates HGF/c-MET pathway (5). BMDCs are activated by factors secreted by stroma cells (SDF-1∝, G-CSF, and IL-6). Inhibition of VEGF
induces endothelial cells apoptosis and pericytes attachment to endothelial cells is loosed (5). New vessels could be recruited to tumour
site by vessel cooption (6). Finally mechanisms involved in tumor anti-angiogenesis resistances lead to select more invasive and metastatic
tumour cells (3).
controlled by HIF-1, and viable circulating endothelial cells
[13, 34, 36].
Hepatocyte Growth Factor (HGF) is a potent mitogenic,
motogenic, morphogenic factor, and also an important actor
in angiogenesis and tumour growth [37–39]. HGF induces
and activates its membrane tyrosine kinase receptor c-MET.
WhereasHGFismostlyproducedbymesenchymalcells[40],
c - M E Ti se x p r e s s e db yd i ﬀerent cell types such as vascular
and lymphatic endothelial cells and pericytes [41]. Thereby,
HGF eﬀects are not limited to endothelial cells. HGF binds
c-METandinducesitshomodimerizationandautophospho-
rylation; then c-MET activates signal transduction pathways
such as Src, Akt, MEK, STAT3 [42] and leads to increase
expression of VEGF and VEGF/R in endothelial cells [43].
C-MET and HGF are deregulated and correlated with poor
prognosis in a lot of human cancers. The receptor can be
constitutively phosphorylated, its gene mutated or ampliﬁed
in tumours. HGF/c-MET promotes cell invasiveness and
triggers metastases through angiogenic pathway [44]. It
has been described, in lung cancer patient specimens, that
HGF is colocalized with ﬁbroblasts. When lung cancer cells
and HGF-producing ﬁbroblasts are injected into mice, the
tumour becomes resistant to EGFR-TKIs treatment. The
stromal ﬁbroblasts seem to an actor in TKI treatment
resistance by producing angiogenic factors such as HGF
[45]. In a pancreatic cancer model it has been shown that
HIF-1 increases c-MET expression in cancer cells and HGF
secretion by ﬁbroblast cells [46]. Hypoxia induces HGF/c-
MET signaling pathway that leads to matrice membrane
degradation and increase of cell migration towards blood or
lymphatic vessels (Figure 1(5)).
The plasma-membrane bound Notch receptor ligand,
Delta-like ligand 4 (DLL4), can be an alternative angiogenic
pathway which participates to anti-angiogenic treatment
failure. DLL4 is highly expressed by vascular endothelial
cells and induced by VEGF. It interacts with Notch cell-
surface receptors to act as a negative feedback inhibitor
downstream of VEGF signaling to restrain the sprouting
and branching of new blood vessels [47, 48]. Inhibition of
DLL4-Notch signaling induces an increase in vessel density4 Journal of Oncology
but these blood vessels are abnormal and not perfused.
Therefore intratumour hypoxia is increased and leads to
induction of transcription of proangiogenic genes regulated
by HIF-1 [48–50]. Moreover, tumours that have an intrinsic
resistance to anti-VEGF therapy are responsive to inhibition
of DLL4/Notch signaling [51].
2.3. Selection of More Invasive Tumour Cells. The angiogenic
inhibitors normalize tumour vasculature, reduce tumour
size, but increase local hypoxia (Figure 1(3)). It has been
shown that tumour cells cultured under hypoxia condi-
tions can become more invasive and metastatic [52]. More
recently, two studies support the hypothesis that under anti-
angiogenic treatment, cancer cells become more invasive
and metastatic to migrate to normoxic location. Thereby,
in mouse models of pancreatic neuron-endocrine carcinoma
and glioblastoma, the primary tumour size decreases after
one week of Sunitinib. This anti-angiogenic treatment seems
to select more aggressive cancer cells and local tumour
cell invasion and distant metastasis are increased. Further-
more, tumours and disseminated liver metastases of animals
present more regions of hypoxia compared to untreated
controltumours.Theproportion ofinvasivetumoursduring
long-term continuous treatment and the invasive phenotype
are not reverse even when the anti-angiogenic treatment is
lifted [53]. Another study suggests, by metastasis assays, that
a short-term of TKIs treatments reduces tumour growth but
increases the incidence of metastasis, facilitates metastatic
dissemination of tumour cells, and decreases overall survival
of animals. This observation is not reverted when mice are
treated one week before tumour cells implantation [54].
2.4. Recruitment of Bone Marrow Derived Proangiogenic Cells
and Inﬂammatory Cells Invasion. Antiangiogenic therapies
normalize vessels but increase intratumoral hypoxia which
lead to recruitment of bone marrow derived cells (BMDCs,
endothelial and pericytes progenitors, tumour associated
macrophages, immature monocytic cell and myeloid cells)
(Figure 1(4)). These cells produce a lot of diﬀerent proan-
giogenic factors and can constitute an adaptive mechanism
of resistance in low oxygen context. Preclinical and clinical
studieshaverevealedthatthenumberofmyeloidcell-derived
suppressor cells (MDSCs), such as CD11b+Gr1+ cells, is
increased in tumours and peripheral blood of tumour-
bearing animals and in blood and spleen of cancer patients
[55]. Furthermore the invasion of tumour by these myeloid
cells is associated with tumour growth and progression and
also contributes to refractoriness to anti-VEGF antibody
treatment [56, 57]. Tumours and stromal cells secrete inter-
leukin 6 (IL-6), SDF-1α, and granulocyte colony-stimulating
factor (G-CSF), three factors implicated in CD11b+Gr1+
cells mobilization and activation [58, 59]. G-CSF expression
by tumour or stromal cells is crucial for refractoriness [56].
Moreover, patients treated by tyrosine kinase inhibitors,
such as Sorafenib or Sunitinib, or by Bevacizumab plus
chemotherapy could be neutropenic [60, 61]. Studies have
shown that with a recombinant G-CSF treatment, the use
of hematopoietic growth factors for treating patients with
neutropenia can mobilize endothelial-cell progenitors and
CD11b+Gr1+ [62–64].
Furthermore, SDF-1α expression by endothelial cells is
increased by HIF-1 following hypoxic conditions. BMDCs
expressed the SDF-1α receptor CXCR4 and are recruited
to the ischemic tissue by cell tropism to SDF-1α. SDF-1α
upregulation is associated with anti-angiogenic treatment
resistance in patients with glioblastoma [13]. Following
Sunitinib treatments, levels of SDF-1α and G-CSF are
increased dose-dependently in healthy mice and cancer
patients [26]. Thereby, in hepatocellular carcinoma, the
plasmatic level increase of SDF-1α and IL-6, in patients
treated with Sunitinib, is associated with a poor outcome
[65]. During Bevacizumab therapy, plasmatic levels of SDF-
1α are increased in patients with rectal cancer and seem to
be associated with distant metastasis after three years [66].
Could SDF-1α be considered as a biomarker of response
or resistance to anti-angiogenic treatment [67]? In response
to SDF-1α and Lysyl Oxidase gradient, CD11b+Gr1+ cells
will be recruited at premetastatic sites and promote tumour
metastasis through matrix metalloproteinase 2 (MMP2)
production [68, 69]. In the tumour microenvironment
and proangiogenic culture conditions, these cells acquire
endothelial cell properties [64]. CD11b+Gr1+ cells promote
tumour angiogenesis by production of angiogenic factors
such as Bv8, a protein related to endocrine-gland derived-
VEGF [63] and matrix degrading enzymes like the matrix
metalloproteinase 9. Some tumours recruit CD11b+Gr1+
cells from the bone marrow to the tumour site and others
do it in response to anti-VEGF treatment [70].
2.5. Tumour-Associated Endothelial Cells and Pericytes.
Tumour-associated endothelial cells and pericytes were
generally assumed to be genetically stable and to have a
low mutational rate [71]. Antiangiogenic therapies target
endothelial cells which develop less drug resistance than
tumour cells. Finally, recent studies have shown that normal
and tumour-associated endothelial cells are diﬀerent and
can be tumour type-dependent, aneuploid, and acquire
genotypic alterations [72, 73]. Therefore, these endothelial
cellalterationsintumourenvironmentcaninduceacomplex
crosstalk between angiogenic pathways and increase anti-
angiogenic therapies resistances. Endothelial cells secrete
PDGF-bb. It mediates proliferation and migration of per-
icytes which express PDGF-R β [74]. Endothelial cells
can induce pericyte recruitment in order to be protected
from anti-VEGF therapy. This leads to an increase of
mature vessels covered with pericytes [75, 76]. Pericytes
are vascular smooth muscle lineage cells closely associated
with the endothelial cells; this contact enhances endothelial
cell survival [77]. These cells are important for vascular
development, endothelial cells permeability, vessel stabiliza-
tion by matrix deposition and/or release, vessel maturation,
and remodeling [78]. Pericytes secrete paracrine factors
that stimulate signaling pathways implicated in endothelial
cell diﬀerentiation and survival and then modulating vessel
stabilization and maturation [74, 79, 80]. Moreover, in
context of tumours or in response to treatments, pericytes
express diﬀerent proteins compared to normal conditionsJournal of Oncology 5
[81]. Anti-VEGF therapies lead to a 80% destruction of the
tumour vasculature [82]. Furthermore, vascular sprouting is
suppressed, blood ﬂow arrested in some vessels, and ﬁnally
some tumour vessels regress and others are normalized [32,
83–85]. Inhibition of VEGF pathway may induce endothelial
cell apoptosis and/or selection of endothelial cells which
express less VEGFR-2 [86]( Figure 1(5)). This reduction
of expression is reversible and high reexpression of this
receptor corresponds with the return of tumour vessels’
dependence for VEGF [20]. VEGFR-2 blockade can lead to
the upregulation of angiopoietin 1 that increases pericyte
coverage of vessels [87]. Despite the endothelial cells’ regres-
sion and pericyte changes, the vascular basal membrane
of tumours persists and provides a potential scaﬀold for
tumour revascularization and a storage site for angiogenic
growth factors [82, 88]. In preclinical study, after 7 days of
treatment, endothelial sprouts grew into empty sleeves of
basal membrane just one day after anti-VEGF withdrawal.
After 7 days, the tumour’s regrowth is complete and pericyte
p h e n o t y p e sr e v e r s et or e t u r nt ob a s e l i n e .F u r t h e r m o r e ,
tumour vessels become functional, reacquire the dependence
to VEGF, and remain sensible to anti-VEGF therapy [20].
Targeting endothelial cells and pericytes by inhibition of
VEGF pathway and PDGF receptor with tyrosine kinase
inhibitors can increase the eﬃcacy of treatments [89].
Moreover, tumour pericytes have abnormal shapes, lose
the attachment to endothelial cells, and contribute to the
aberrant tumour vasculature [90]. Contrariwise, the loss
of pericyte attachment may disrupt the vascular integrity,
increases the risk of hemorrhage, and facilitates the transit
and dissemination of tumour cells in circulatory system.
2.6. Vessel Cooption. Patients treated by anti-angiogenic
therapy are mainly patients with metastases for which other
treatmentsarenolongeravailable.Invasculature-richorgans
such as brain, liver, and lung, primary tumours cells and
metastases could coopt with the neighboring quiescent
normal blood vessels [91]( Figure 1(6)). In rat brain, one or
two weeks after C6 glioma cell implantation, small tumours
are vascularized without angiogenic response [92]. In early
stage of cooption, the tumour growth is angiogenesis inde-
pendent. Tumours vessels display characteristics of normal
vessels. Hence, they will be less sensitive to anti-angiogenic
molecules [93, 94].
3. Conclusion
The establishment of a new vascular network by angio-
genic process is one part of the basis of solid tumour
development and dissemination of tumour cells in the
organism as metastasis. The core of the tumour rapidly
undergoes hypoxic and tumour cells counteract this process
by producing angiogenic factors responsible for growth and
migration of quiescent endothelial cells of proximal blood
vessels. Among the angiogenic factors, the VEGF is one of
the most important. Targeting the VEGF/VEGFR pathway
represents a major advance in cancer treatments and an
important therapeutic option. Despite the transient eﬀect of
these expansive anti-VEGF treatments, the enduring clinical
responses are rare. Pre-clinical and clinical trials suggest a
host response to VEGF inhibition implicated in treatment
failure and can participate to progression of secondary
disease. Furthermore, the mechanisms of action of anti-
angiogenic drugs and resistances against these molecules
vary according to the tumour. Resistance or evasion to
anti-angiogenic therapies in preclinical models is more and
more reported. For example, anti-angiogenic treatments
not only normalize tumour vasculature but also reduce
pericyte coverage and increase tumour hypoxia and tumour
cells can acquire a more invasive; however the molecular
mechanisms are not fully understood. Hence, it is crucial
to highlight molecular mechanisms or actors implicated in
this phenomenon of resistance in order to anticipate the best
responders to the treatment and to improve anti-angiogenic
drugs or to develop new agents. Tumours produce multiple
factors and animal models suggest that diﬀerent pathways
are activated under or following anti-angiogenic therapies.
Hence, targeting complementary pathways implicated in
tumour angiogenesis would be more eﬃcient. At last, it
is also important to ﬁnd predictive biological markers
of objective response or involved in resistance to anti-
angiogenic drugs in order to improve therapy eﬃcacy or
to propose alternative anti-angiogenic therapy in case of
treatment failure.
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